Compare
Shattuck Labs, Inc. vs 60 Degrees Pharmaceuticals, Inc. vs Dare Bioscience, Inc. vs Rafael Holdings, Inc.
| Latest fiscal year | Shattuck Labs, Inc. STTK | 60 Degrees Pharmaceuticals, Inc. SXTP | Dare Bioscience, Inc. DARE | Rafael Holdings, Inc. RFL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-07-31 |
| Revenue | $1.00M | $1.01M | $1.03M | $917.0K |
| Revenue growth (YoY) | -82.5% | +65.5% | n/m | +44.0% |
| Gross margin | n/a | 22.3% | 71.3% (computed) | n/a |
| Operating margin | n/m | -771.6% | n/m | n/m |
| Net margin | n/m | -732.5% | n/m | n/m |
| Net income | -$48.81M | -$7.37M | -$13.40M | -$30.52M |
| EPS (Diluted) | -$0.70 | -$11.73 | -$1.20 | -$1.04 |
| Operating cash flow | -$39.88M | -$6.85M | -$9.90M | -$18.92M |
| Free cash flow | -$39.95M | -$6.99M | -$10.29M | -$18.93M |
| Cash & equivalents | $54.19M | $1.51M | $24.71M | $52.77M |
| Total assets | $91.03M | $5.37M | $32.47M | $114.11M |
| Total liabilities | $8.64M | $1.99M | $29.63M | $15.74M |
| Shareholders' equity | $82.39M | $3.46M | $2.84M | $98.37M |
| Return on year-end equity | -59.2% | -212.7% | -471.4% | -31.0% |
| Shares outstanding | 63.28M | 1.16M | 14.50M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Shattuck Labs, Inc. | 60 Degrees Pharmaceuticals, Inc. | Dare Bioscience, Inc. | Rafael Holdings, Inc. |
|---|---|---|---|---|
| Latest | $1.00M Ended 2025-12-31 | $1.01M Ended 2025-12-31 | $1.03M Ended 2025-12-31 | $917.0K Ended 2025-07-31 |
| 1 year earlier | $5.72M Ended 2024-12-31 | $607.6K Ended 2024-12-31 | $9.8K Ended 2024-12-31 | $637.0K Ended 2024-07-31 |
| 2 years earlier | $1.66M Ended 2023-12-31 | $253.6K Ended 2023-12-31 | $2.81M Ended 2023-12-31 | $279.0K Ended 2023-07-31 |
| 3 years earlier | $652.0K Ended 2022-12-31 | $223.2K Ended 2022-12-31 | $10.00M Ended 2022-12-31 | $410.0K Ended 2022-07-31 |
| 4 years earlier | $30.02M Ended 2021-12-31 | n/a | $0 Ended 2021-12-31 | $802.0K Ended 2021-07-31 |